Information  X 
Enter a valid email address

Sensyne Health PLC (SENS)

  Print      Mail a friend

Friday 23 October, 2020

Sensyne Health PLC

Sensyne Health agreement with Bristol Myers Squibb

RNS Number : 9766C
Sensyne Health PLC
23 October 2020
 

Sensyne Health signs agreement with Bristol Myers Squibb to apply machine learning for rare blood disease research

 

 

Oxford, U.K. 23 October 2020:   Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces it has signed a research collaboration agreement with Bristol Myers Squibb ("BMS"). 

 

Initially the collaboration will focus on applying Sensyne's proprietary machine learning to conduct research into disease progression and patient stratification for patients with various diseases within the broader group of Myeloproliferative Neoplasms ("MPNs"). MPNs comprise a group of rare blood diseases characterised by the overproduction of one or more types of blood cells - red blood cells, white blood cells and platelets.  

 

The collaboration will be Sensyne Health's fourth successive partnership with a major pharmaceutical company following collaborations signed with Bayer, Roche and Alexion.

 

No financial terms have been disclosed.

 

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"This new collaboration with one of the world's leading pharmaceutical companies is a further validation of Sensyne's unique model whereby Sensyne acts as the docking station between the pharmaceutical industry and providers of health data to allow for the ethical commercialisation of such data. As we continue to see wider adoption of Clinical AI and machine learning by the life sciences industry to support pharmaceutical research, Sensyne is ideally positioned to help accelerate the discovery and development of new medicines for patients."

 

 

 

 

-ENDS-

 

For more information please contact:

Sensyne Health ( www.sensynehealth.com )

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer


Michael Norris, Interim Chief Financial Officer


 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden


James Steel


Oliver Jackson


Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma


Euan Brown


Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott


Sukaina Virji


Melissa Gardiner


CSCS [email protected]


 

 

 

About Sensyne Health  

 

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRPPGMAUUPUGQP

a d v e r t i s e m e n t